Ticagrelor
Kāpae
ʻO Ticagrelor kahi mea kū'ē hou o ka P2Y12 receptor [1].
Ua hōʻike ʻia ʻo Ticagrelor e kāohi i nā hopena prothrombotic o ADP ma ka platelet e kūʻē i ka P2Y12 receptor. Ua hōʻike ʻo Ticagrelor i ka pale piha ʻana o ka platelet aggregation ex vivo. Eia kekahi, ua ʻōlelo ʻo Ticagrelor i ka hoʻopaʻa ʻana i ka hopena o ka platelet aggregation i ke kanaka. Ma waho aʻe o kēia mau mea, ua hōʻike pū ʻo Ticagrelor i kahi antagonist paʻa waha, ikaika, reversibly. ʻAʻole e like me nā mea hoʻopaneʻe ʻē aʻe, ua hōʻike pū ʻo Ticagrelor e kāohi i ka receptor P2Y12 me ka ʻole o ka hoʻololi metabolic. Ma waho aʻe o kēlā, ʻo Ticagrelor ka mea mua thienopyridine anti-platelet agent a me ka nui o ka metabolized e CYP3A4 a me CYP2C19 [1] [2].
Kuhikuhi:
[1] Zhou D1, Anderson TB, Grimm SW. ʻO ka loiloi in vitro o ka pili ʻana i ka lāʻau lapaʻau me ka ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. ʻO ka lāʻau lapaʻau Metab Dispos. 2011 Apr;39(4):703-10.
[2] Li Y1, Landqvist C, Grimm SW. ʻO ka hoʻokaʻawale a me ka metabolism o ticagrelor, kahi moʻolelo P2Y12 receptor antagonist, i nā ʻiole, nā ʻiole, a me nā marmosets. ʻO ka lāʻau lapaʻau Metab Dispos. 2011 Sep;39(9):1555-67. doi: 10.1124/dmd.111.039669. Epub 2011 Iune 13.
wehewehe
ʻO Ticagrelor (AZD6140) he antagonist receptor P2Y12 oral reversible no ka mālama ʻana i ka platelet aggregation.
In Vitro
Hoʻolaha ʻo Ticagrelor i kahi kaohi nui o ka adenosine 5'-diphosphate (ADP)–hoʻokuʻu ʻia ʻo Ca2+ i loko o nā platelet ished me nā mea kūʻē P2Y12R ʻē aʻe. ʻO kēia hopena hou aʻe o ka ticagrelor ma mua o ka P2Y12R antagonism he hapa ia o ka ticagrelor e kāohi ana i ka equilibrative nucleoside transporter 1 (ENT1) ma nā platelets, e alakaʻi ana i ka hōʻiliʻili ʻana o ka adenosine extracellular a me ka hoʻoulu ʻana o Gs-coupled adenosine A2A receptors [1]. Hōʻike nā pūnaewele B16-F10 i ka emi ʻana o ka launa pū ʻana me nā platelets mai nā ʻiole i mālama ʻia e ticagrelor i hoʻohālikelike ʻia me nā ʻiole i mālama ʻia i ka saline [2].
Ma ka B16-F10 melanoma intravenous a intrasplenic metastasis models, nāʻiole i mālamaʻia me ka lāʻau lapaʻau o ticagrelor (10 mg / kg) e hōʻike ana i ka emiʻana o ka māmā (84%) a me ka ate (86%) metastases. Eia kekahi, hoʻomaikaʻi ka lāʻau ticagrelor i ke ola ma mua o nā holoholona i mālama ʻia i ka saline. ʻIke ʻia kahi hopena like i kahi ʻano maʻi maʻi umauma 4T1, me ka hōʻemi ʻana i ka māmā (55%) a me ka iwi iwi (87%) metastases ma hope o ka mālama ʻana i ka ticagrelor [2]. ʻO ka hoʻokele waha waha hoʻokahi o ticagrelor (1-10 mg / kg) ke kumu i ka hopena inhibitory pili i ka hopena ma ka platelet aggregation. ʻO Ticagrelor, ma ke kiʻekiʻe kiʻekiʻe (10 mg / kg) kaohi nui i ka platelet aggregation ma 1 h ma hope o ka hoʻopaʻa ʻana a ʻike ʻia ka inhibition kiʻekiʻe ma 4 mau hola ma hope o ka dosing.
Waihona
4°C, pale mai ka malamalama, mālama ʻia ma lalo o ka nitrogen
*Ma ka solvent: -80°C, 6 mahina; -20°C, 1 mahina (pale mai ka malamalama, mālama ʻia ma lalo o ka nitrogen)
ʻO ke kinona





Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6apono ʻia nā papahana.

Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.

Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.

Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kākau inoa ʻana.


Kolea Countec Bottled Packaging Line


ʻO Taiwan CVC Bottled Packaging Line


Italia CAM Board Packaging Line

Mekini Fette Compacting German

ʻO Iapana Viswill Tablet ʻIke

Keena Mana o DCS

